NextCure (NXTC) Free Cash Flow (2018 - 2026)
NextCure (NXTC) posted quarterly Free Cash Flow of -$13.4 million for Q1 2026, down 2.84% year-over-year from -$13.8 million in Q1 2025, and down 74.95% quarter-over-quarter from -$7.6 million in Q4 2025.
NextCure (NXTC) Free Cash Flow (2018 - 2026) Analysis & Trends
NextCure's Free Cash Flow history runs 9 years deep, the most recent figure standing at -$13.4 million for Q1 2026.
- In Q1 2026, Free Cash Flow fell 2.84% year-over-year to -$13.4 million; the TTM figure through Mar 2026 stood at -$50.0 million (down 20.06% YoY), while the FY2025 annual figure was -$49.6 million, down 20.19% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$13.4 million, down from -$7.6 million in the prior quarter.
- The five-year high for Free Cash Flow was -$6.3 million in Q3 2025, with the low at -$22.7 million in Q2 2025.
- The 5-year median for Free Cash Flow is -$13.0 million (2025), against an average of -$12.6 million.
- Peak annual rise in Free Cash Flow reached 46.08% in 2025, while the deepest fall reached 125.39% in 2025.
- NextCure's Free Cash Flow stood at -$9.8 million in 2022, then retreated by 8.85% to -$10.7 million in 2023, then soared by 35.08% to -$6.9 million in 2024, then retreated by 10.14% to -$7.6 million in 2025, then plunged by 74.95% to -$13.4 million in 2026.
- Business Quant data shows NXTC's Free Cash Flow at -$13.4 million in Q1 2026, -$7.6 million in Q4 2025, and -$6.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | NextCure | 33.72 Mn | 33.72 Mn | - | -9.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -9.72 Mn |
| Jun 30, 2026 | -9.72 Mn |
| Mar 31, 2026 | -13.36 Mn |
| Mar 31, 2026 | -13.36 Mn |
| Dec 31, 2025 | -7.64 Mn |
| Dec 31, 2025 | -7.64 Mn |
| Sep 30, 2025 | -6.27 Mn |
| Sep 30, 2025 | -6.27 Mn |
| Jun 30, 2025 | -22.71 Mn |
| Jun 30, 2025 | -22.71 Mn |
| Mar 31, 2025 | -12.99 Mn |
| Mar 31, 2025 | -12.99 Mn |
| Dec 31, 2024 | -6.94 Mn |
| Dec 31, 2024 | -6.94 Mn |
| Sep 30, 2024 | -11.62 Mn |
| Sep 30, 2024 | -11.62 Mn |
| Jun 30, 2024 | -10.08 Mn |
| Jun 30, 2024 | -10.08 Mn |
| Mar 31, 2024 | -12.64 Mn |
| Mar 31, 2024 | -12.64 Mn |